Full-Time

Senior Director – Global Commercial Strategy Lead

MM

Posted on 11/26/2025

Deadline 12/2/25
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$173k - $299k/yr

+ Annual performance bonus

Bridgewater Township, NJ, USA

In Person

Requires up to 30% travel, including international travel.

Category
Growth & Marketing (2)
,
Required Skills
Branding/Brand Strategy
Data Analysis
Requirements
  • Required Minimum Education: A minimum of a Bachelor's degree is required. An advanced degree in business or life sciences is preferred.
  • Required Years of Related Experience: A minimum of 10 years of progressive biotech, pharmaceutical or relevant experience is required.
  • In-line marketing experience with senior brand responsibility and people management in dynamic and innovative specialty therapeutic area. Oncology/hematology experience is strongly preferred.
  • Exceptional strategic thinking and analytical skills, ability to master complexity and to integrate insights into strategies and actions
  • Demonstrated ability to work cross-functionally and cross-geography.
  • Other preferred qualifications: Launch experience, Global experience, demonstrated ability to work with regional partners, experience with managing strategic alliances, global market access and medical strategy
  • Proven track record of exceptional team & cross functional leadership.
  • Exceptional executive presence and strong communication skills, ability to work with senior leaders and executives
  • General manager leadership skills and enterprise mentality, ability to influence across the organization
  • Demonstrated innovation and agility to navigate multifaceted ecosystems
  • Ability to assimilate complex science and medical data
  • Ability to run multiple demands and priorities on time, lead teams, gain alignment and driving decision making is required.
  • This position requires up to 30% travel (largely international).
Responsibilities
  • Lead the Global Commercial Team (GCT) across both brands with representation from NA, EMEA, AP, LA and other key stakeholders to develop and execute global commercial and brand strategy.
  • Drive development of key components of commercial strategy, including brand development, public relations, medical strategy, market access/reimbursement strategies, and other market preparation programs across both brands.
  • Build strategies and innovative go-to market approaches across both brands for flawless launch and seamless customer experience in partnership with regional operating companies.
  • Collaborate with regional partners to lead the creation and execution of well-coordinated commercial strategies and launch plans across both brands, embedding external customer insights from patients, health care providers, pathology/testing labs and payers. Embed an increasingly digital/omnichannel mindset in our go to market models.
  • Effectively partner with R&D and Regions to coordinate commercial plans across both brands with operational strategy as well as key holistic brand messaging.
  • Effectively partner with R&D in Compound Development Teams and within the Disease Area Strategy forums, and the regional leadership to provide input into product development, label optimization, evidence generation, lifecycle decisions, formulation and dosing enhancements that supports the commercial launch strategy and lifecycle management investments across both brands.
  • Lead the development of strong business case for new investments and lead/represent global commercial point of view through governance process across both brands.
  • Provide commercial input into the full asset valuation in collaboration with the Global Commercial insights and Analytics team. Leverage knowledge of the current and future market to provide insights for forecasting, strategic planning, and business planning in close collaboration with business analytics partners for competitive Intelligence, market research and forecasting across both brands.
  • Accountable for managing marketing strategy budget across both brands.
  • Demonstrate strong external focus by active engagement with key stakeholders including Key Opinion Leaders and Patient Opinion Leaders.
  • Support the development of a robust portfolio strategy in Multiple Myeloma providing commercial input and aligned business plan.
  • Be the ambassador for GCSO to attract, develop, and retain high performing talent.
  • Build vibrant team culture and shape next generation of commercial leaders.
Desired Qualifications
  • Launch experience
  • Global experience
  • demonstrated ability to work with regional partners
  • experience with managing strategic alliances
  • global market access and medical strategy
  • Demonstrated ability to lead and develop teams
  • Experience with cross-functional leadership across global regions
  • Strong communication skills with senior leaders
  • Experience traveling up to 30% internationally
  • Advanced degree in business or life sciences (preferable)
  • Experience in oncology/hematology preferred

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hit $24.1 billion, up 9.9%, raising 2026 forecast to $100.8 billion.
  • Nipocalimab gains FDA Priority Review for autoimmune hemolytic anemia and myasthenia gravis efficacy.
  • Shockwave C2 Aero launches in US and Japan targeting 315 million calcified CAD patients.

What critics are saying

  • Stelara sales plunge 60% to $656 million in Q1 2026 post-patent expiration, creating $2.3 billion hole.
  • Icotyde stalls at 1,500 prescriptions, missing oncology targets by Q3 2026.
  • CAPLYTA faces Invega Sustenna competition, achieving under 10% adoption by mid-2027.

What makes Johnson & Johnson unique

  • J&J unites Innovative Medicine and MedTech under single brand since September 2023.
  • DARZALEX and TREMFYA dominate oncology and immunology with $57 billion pharma sales in 2024.
  • CARTO System leads electrophysiology for 30 years with AI-powered CARTOSOUND SONATA.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Johnson & Johnson who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Company News

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.

INACTIVE